Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190924 | 0.81 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL13875525 | 0.81 | CHRM2 (0.47) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4619067 | 0.76 | CHRM2 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4200185 | 0.75 | CHRM3 (0.45) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4186752 | 0.73 | CHRM3 (0.43) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4129264 | 0.72 | CHRM2 (0.46) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4191393 | 0.69 | CHRM3 (0.67) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4193806 | 0.69 | CHRM3 (0.49) | CHRM3 | |
| SCHEMBL4757575 | 0.68 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL3216726 | 0.68 | ALDH1A1 (0.49) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | claimed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | claimed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | claimed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.